Masterclass: Non‑melanoma skin cancer (BCC, cSCC, MCC)

Описание: ABSITE Daily Dose – “One concept a day to score 99% on test day.”

For residents who want automatic, pattern‑recognition instincts on non‑melanoma skin cancer (BCC, cSCC, MCC):

A masterclass that turns scattered skin‑cancer facts into a tight, visual decision tree you can run in your head in seconds.
Built to hard‑wire risk stratification, margins, SLNB, and adjuvant therapy—so you answer faster, operate safer, and think like a boards‑ready skin oncology surgeon.

Addendum - 5:55 Asymptomatic


BIBLIOGRAPHY

“Navigating Cutaneous Squamous Cell Carcinoma: Epidemiological Trends, Treatment Strategies, and Collaborative Care Approaches.” American Journal of Managed Care. Accessed February 14, 2026.

“Basal Cell and Squamous Cell Skin Cancers.” Journal of the National Comprehensive Cancer Network. Accessed February 14, 2026.

“Basal Cell and Squamous Cell Skin Cancers.” ResearchGate (PDF). Accessed February 14, 2026.

“A Practical Guide for the Follow‑Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors.” PubMed Central. Accessed February 14, 2026.

“Pharmacokinetics and Pharmacodynamics of Hedgehog Pathway Inhibitors Used in the Treatment of Advanced or Treatment‑Refractory Basal Cell Carcinoma.” Taylor & Francis. Accessed February 14, 2026.

“Clinical Outcomes of Sonidegib in Vismodegib‑Exposed Locally Advanced Basal Cell Carcinoma: Insights From a Multicenter Descriptive Study.” PubMed Central. Accessed February 14, 2026.

“Characterization and Management of Hedgehog Pathway Inhibitor‑Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.” PubMed Central. Accessed February 14, 2026.

“Managing Advanced Basal Cell Carcinoma: A Guide for the Dermatology Clinician.” Journal of Clinical and Aesthetic Dermatology. Accessed February 14, 2026.

“Management of High‑Risk Cutaneous Squamous Cell Carcinoma.” Alberta Health Services. Accessed February 14, 2026.

“Management of Regional Lymph Nodes in Clinically Node‑Negative Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Systematic Review and Meta‑Analysis.” MDPI. Accessed February 14, 2026.

“A Comprehensive Narrative Review of the Challenges Surrounding Cutaneous SCC.” PubMed Central. Accessed February 14, 2026.

“Immunotherapy and Radiation for Clinical Perineural Invasion in Cutaneous Squamous Cell Carcinoma.” MDPI. Accessed February 14, 2026.

“Before, After, or Both? Rethinking the Timing of Immunotherapy in Cutaneous Squamous Cell Carcinoma.” American Head & Neck Society. Accessed February 14, 2026.

“Evolving Standards for Resected High‑Risk CSCC: Integrating Insights from C‑POST and KEYNOTE‑630.” Journal of Cutaneous Oncology. Accessed February 14, 2026.

“Merkel Cell Carcinoma: Clinical Practice Guidelines in Oncology.” PubMed Central. Accessed February 14, 2026.

“Toward Better Management of Merkel Cell Carcinoma Using a Consensus Staging System, New Diagnostic Codes and a Recently Discovered Virus.” PubMed Central. Accessed February 14, 2026.

“Circulating Tumor DNA Level Is Associated with Time to Clinical Recurrence in Merkel Cell Carcinoma: Implications for Patient Management.” PubMed Central. Accessed February 14, 2026.

“The Evolving Role of ctDNA in Merkel Cell Carcinoma: Challenges and Opportunities.” Accessed February 14, 2026.

“Scottish Consensus Clinical Management Guideline: Merkel Cell Cancer.” NHS Scotland North. Accessed February 14, 2026.

“Should Subclinical (ctDNA Positive) Merkel Cell Carcinoma Be Treated With Immunotherapy? A Proposed Randomized Clinical Trial.” Merkel Cell Carcinoma Institute. Accessed February 14, 2026.